Patient Decision Aid for Chronic Myeloid Leukemia Dose Reduction
Author Information
Author(s): D. N. Lokhorst, M. F. Djodikromo, R. P. M. G. Hermens, N. M. A. Blijlevens, C. L. Bekker
Primary Institution: Radboud University Medical Center
Hypothesis
Can a patient decision aid improve decision-making for chronic myeloid leukemia patients considering dose reduction of tyrosine kinase inhibitors?
Conclusion
A well-accepted online patient decision aid for chronic phase CML patients to consider TKI dose reduction was developed.
Supporting Evidence
- 76% of patients and 100% of healthcare providers recommended the PDA.
- The PDA was considered clear, balanced, and helpful for decision-making.
- Patients valued the PDA for preparing for consultations with healthcare providers.
Takeaway
This study created a helpful tool for patients with chronic myeloid leukemia to understand their options for reducing medication doses.
Methodology
The patient decision aid was developed through needs assessments, iterative feedback, and alpha-testing with patients and healthcare providers.
Potential Biases
Potential selection bias due to recruitment methods favoring more engaged patients.
Limitations
The PDA was developed in Dutch, which may limit accessibility for non-Dutch speakers.
Participant Demographics
Patients included a mix of ages and educational backgrounds, with a majority being male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website